RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiadis Pharma Stock

Kiadis Pharma P/E 2024

Kiadis Pharma P/E

-4.96

Ticker

KDS.AS

ISIN

NL0011323407

WKN

A14VE3

As of Nov 5, 2024, Kiadis Pharma's P/E ratio was -4.96, a 0% change from the 0 P/E ratio recorded in the previous year.

The Kiadis Pharma P/E history

Kiadis Pharma Aktienanalyse

What does Kiadis Pharma do?

Kiadis Pharma NV was founded in 1997 in Amsterdam and is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases. The company is based in the Netherlands and is listed on the Euronext Amsterdam stock exchange. The business model of Kiadis is based on the development of therapies for patients with high medical needs, especially for individuals with severe blood cancer diseases for which there are no cure options. The company employs a proprietary platform technology that is based on the activation of T-cells for the therapy of cancer patients. Kiadis is currently developing various therapeutic approaches for the treatment of blood cancer diseases such as leukemia, lymphoma, and multiple myeloma. The company's main products are ATIR101 and ATIR201. ATIR101 is a cell therapy for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) who require an allogeneic stem cell transplant. This therapy aims to reduce the risk of transplant rejection and graft-versus-host disease (GVHD), thereby increasing patients' chances of survival. ATIR201 is a therapy for the treatment of patients with multiple myeloma who require an allogeneic stem cell transplant. This therapy aims to reduce the risks of transplant rejection and GVHD, thereby increasing patients' chances of survival. Kiadis has also developed another platform technology called CytoSen, which is based on the activation of NK cells for the immunotherapy of cancer. The CytoSen technology aims to enhance the effectiveness of T-cell therapy by combining it with NK cells. Kiadis is continuously working to improve and expand its products and therapies. The company has a strong pipeline of product candidates at various stages of development targeting the treatment of leukemia, lymphoma, multiple myeloma, and other cancer diseases. The company has also entered into a partnership with Sanofi to accelerate the development of its therapies. Overall, Kiadis Pharma NV has an impressive history as an innovative company with a clear focus on the development of cell therapies for the treatment of blood cancer diseases. The company is dedicated to improving the lives of cancer patients and continuously works on the development of new therapies to improve the chances of survival and quality of life for cancer patients worldwide. Kiadis Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Kiadis Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Kiadis Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Kiadis Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Kiadis Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Kiadis Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Kiadis Pharma stock

What is the price-to-earnings ratio of Kiadis Pharma?

The price-earnings ratio of Kiadis Pharma is currently -4.96.

How has the price-earnings ratio of Kiadis Pharma changed compared to last year?

The price-to-earnings ratio of Kiadis Pharma has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Kiadis Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Kiadis Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Kiadis Pharma affect the company?

An increase in the price-earnings ratio of Kiadis Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Kiadis Pharma affect the company?

A decrease in the price-earnings ratio of Kiadis Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Kiadis Pharma?

Some factors that influence the price-earnings ratio of Kiadis Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Kiadis Pharma pay?

Over the past 12 months, Kiadis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiadis Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Kiadis Pharma?

The current dividend yield of Kiadis Pharma is .

When does Kiadis Pharma pay dividends?

Kiadis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiadis Pharma?

Kiadis Pharma paid dividends every year for the past 0 years.

What is the dividend of Kiadis Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiadis Pharma located?

Kiadis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiadis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiadis Pharma from 11/5/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Kiadis Pharma pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Kiadis Pharma in the year 2023?

In the year 2023, Kiadis Pharma distributed 0 EUR as dividends.

In which currency does Kiadis Pharma pay out the dividend?

The dividends of Kiadis Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Kiadis Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Kiadis Pharma

Our stock analysis for Kiadis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiadis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.